Search clinical trials for: exemestane (Aromasin)

Total 455 results

Actavis Inc.

Withdrawn

Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects

Healthy

South Africa
Pfizer

Terminated

Evaluating The Safety Of Exemestane Following 2-3 Years Of Adjuvant Tamoxifen Therapy In Postmenopausal Early Breast Cancer Patients

Early Breast Cancer
Pfizer

Completed

Sequencing Of Endocrine Therapy In Post-Menopausal Women With Early Breast Cancer (FAST) (FAST)

Post Menopausal Women With Early Breast Cancer
Biogen

Completed

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Breast Cancer

United States, Russian Federation, Australia, Belgium
Pfizer

Completed

Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane (TEAM)

Breast Neoplasms

United States
Jules Bordet Institute
Novartis

Completed

Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women (PEARL)

Breast Cancer

Belgium
Pfizer

Completed

Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China

Breast Neoplasms

China
Roxane Laboratories

Completed

Pilot Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

Breast Cancer

United States
Roxane Laboratories

Completed

Bioequivalency Study of Exemestane 25 mg Tablet Under Fed Conditions

Breast Cancer

United States
Pfizer

Terminated

An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin

Breast Neoplasms

India
Roxane Laboratories

Completed

Bioequivalency Study of Exemestane 25 mg Tablet Under Fasted Conditions

Breast Cancer

United States
Pfizer

Completed

Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients

Breast Neoplasms

France
Pfizer

Terminated

A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer

Invasive Early Breast Cancer

Romania
Hellenic Breast Surgeons Society

Terminated

Adjuvant Post-Tamoxifen Exemestane Trial (ATENA)

Breast Cancer

Greece
Pfizer

Completed

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Breast Cancer

Korea, Republic of
Pfizer
Astellas Pharma Inc; Medivation, Inc.

Active, not recruiting

Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Breast Cancer

United States, Spain, Belgium, Canada, Italy, Ireland, United Kingdom
Chipscreen Biosciences, Ltd.

Completed

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Breast Cancer

China
First Affiliated Hospital of Zhejiang University

Recruiting

Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Estrogen Receptor Positive Tumor

China
University of Michigan Rogel Cancer Center
Damon Runyon Cancer Research Foundation

Completed

Pilot Study to Evaluate the Effect of Aromatase Inhibitor Therapy on Pain Threshold in Breast Cancer Patients

Pain | Breast Cancer | Arthralgia

United States
Syndax Pharmaceuticals

Completed

Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer (ENCORE301)

Breast Cancer | ER+ Breast Cancer | Estrogen Receptor-Positive Breast Cancer | Breast Cancer, Estrogen Receptor-Positive

United States, Czechia, Canada, Hungary, Russian Federation
Centre Leon Berard

Recruiting

Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS) (BFR-ESS)

Low Grade Endometrial Stromal Sarcoma

France
Syndax Pharmaceuticals

Completed

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States
Pfizer

Completed

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

Breast Neoplasms

Belgium, Brazil, United States, India, Peru, Philippines, Mexico, Canada, Colombia
Atossa Therapeutics, Inc.
InClin

Recruiting

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer (EVANGELINE)

Breast Neoplasms | Invasive Breast Cancer | HER2-negative Breast Cancer | Estrogen-receptor-positive Breast Cancer

United States
Pfizer

Completed

Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer

Metastatic Breast Cancer

China
AstraZeneca

Completed

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Progression-free Survival

Korea, Republic of
Masonic Cancer Center, University of Minnesota

Completed

Exemestane in Post-Menopausal Women With NSCLC

Non-Small Cell Lung Cancer

United States
Pfizer

Completed

Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer (TEAM)

Breast Neoplasms

France
Pfizer

Completed

Special Investigation For Patients With Renal And/Or Hepatic Disorders On Aromasin

Breast Neoplasms
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer

Breast Cancer

United States
Nordic Society of Gynaecological Oncology - Clinical...

Completed

Exemestane in Advanced and Recurrent Endometrial Carcinoma

Endometrial Cancer

Norway
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Terminated

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Breast Cancer | Hormone Receptor Positive Tumor

United States
National University Hospital, Singapore

Unknown

Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD

Breast Carcinoma

Singapore
Pfizer

Terminated

A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients (ETAPE)

Breast Cancer
Pfizer

Terminated

Aromasin® As Adjuvant Treatment In Postmenopausal Women With Invasive, Estrogen Receptor Positive Early Breast Cancer

Breast Neoplasms

Serbia, Croatia, Estonia
University of Michigan Rogel Cancer Center

Completed

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer (LOGRIBMET)

Obesity | Breast Cancer | Arthralgia

United States
Organisation for Oncology and Translational Research

Unknown

Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer

Hormone Receptor Positive Malignant Neoplasm of Breast

China
Veronica Morgan Jones

Recruiting

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Breast Cancer | Breast Carcinoma | HER2-negative Breast Cancer | Node-negative Breast Cancer

United States
Ohio State University Comprehensive Cancer Center
Pfizer

Completed

Exemestane in Combination With Fulvestrant in Postmenopausal Women With Hormone Sensitive Advanced Breast Cancer

Breast Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064)

Breast Neoplasms
Merrimack Pharmaceuticals

Completed

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Her2 Negative Breast Cancer Patients

United States, Spain, Canada, Germany, Russian Federation
Institute of Cancer Research, United Kingdom

Recruiting

PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (POETIC-A)

Breast Cancer Female

United Kingdom
University of Colorado, Denver

Completed

Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors

Breast Cancer | Stage II Breast Cancer | Stage III Breast Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer

Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia | FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | Atypical Hyperplasia

United States
M.D. Anderson Cancer Center
Susan G. Komen Breast Cancer Foundation

Terminated

Exemestane-RAD001-Metformin

Breast Cancer

United States
AstraZeneca

Completed

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer (EFECT)

Metastatic Breast Cancer | Locally Advanced Breast Cancer

Sweden, United States, Russian Federation, South Africa, United Kingdom, Germany, Hungary, Canada, Belgium, Denmark, Israel, Argentina, France, Brazil, Spain
Finn, Olivera, PhD
Breast Cancer Research Foundation; A Glimmer of Hope Foundation

Recruiting

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Ductal Carcinoma in Situ

United States
Spanish Breast Cancer Research Group
Pfizer

Completed

Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients

Breast Cancer

Spain
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

Solid Tumors and Lymphomas

United States
Gilead Sciences

Terminated

GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer

Advanced Estrogen Receptor Positive HER2- Breast Cancer

United States

3

Subscribe